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ABSTRACT
Glucocorticoids (GCs) are routinely administered systemically or injected into the eye when treating numerous ocular
diseases; however, their toxicity on the retinal microvasculature has not been previously investigated. In this article, the
effects of hydrocortisone (Hydro), dexamethasone, dexamethasone-phosphate and triamcinolone acetonide (TA) were
evaluated in vitro on human skin microcirculation cells and, bovine endothelial retinal cells, ex-vivo, on flat mounted rat
retinas. The degree of GCs induced endothelial cell death varied according to the endothelial cell type and GCs chemical
properties. GCs toxicity was higher in skin microvascular endothelial cells and for hydrophobic GC formulations. The
mechanism of cell death differed between GCs, Hydro and TA activated the leukocyte elastase inhibitor/L-DNase II
pathways but did not activate caspases. The mechanisms of cell death observed in cell cultures were similar to those
observed in rat retinal explants. Taken together these results indicate that particular attention should be paid to the
potential vascular side effects when administrating GCs clinically and in particular when developing sustained-release
intraocular devices.
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Glucocorticoids (GCs) hormones easily cross cell membranes
due to their lipophilicity and exert physiological effects in al-
most every tissue of the human body (Cockrem, 2013; Walker
et al., 2012). Synthetic or semi-synthetic GCs aim to optimize the
immunosuppressive, angiostatic, and anti-inflammatory prop-
erties of cortisol, while reducing their mineralocorticoid side ef-
fects. GCs remain the first-line therapy in number of
inflammatory conditions and are administered locally or sys-
temically (Barnes, 2005; Logie et al., 2010). Recognized side
effects of GCs include microvascular fragility, atrophy, as well
as reduced microvascular density in skin, bone, and muscle
(Anacker et al. 2011; Schacke et al. 2002; Torriglia et al., 2010).
Folkman et al. demonstrated that hydrocortisone (Hydro)
and dexamethasone (Dexa) at micrograms per microliters
concentrations prevent heparin-stimulated angiogenesis in the
chick chorioallantoic membrane and induce the regression of
capillaries within the surrounding tissue (Folkman et al., 1983;
Folkman and Ingber, 1987). Later, Small et al. showed that corti-
costerone (300–600 nM) inhibits angiogenesis in vitro and in vivo.
In addition, inhibition of 11-beta-hydroxysteroid dehydroge-
nase type 1 favors corticosterone production and enhances an-
giogenesis providing evidence for the angiostatic role of
endogenous corticosteroids (Small et al., 2005). More recently,
the mechanisms of the angiostatic effects of physiological doses
of the endogenous corticosterone have been studied in more de-
tails, revealing a receptor-mediated effect on vascular endothe-
lial growth factor production, activation of matrix metallo
peptidase 2, and the inhibition of endothelial cells tube-like
structure formation (Shikatani et al., 2012). Systemic adminis-
tration of GCs triggered cell death of macrophages (Schmidt
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et al., 1999), human epithelial cells of the lens (Sharma et al.,
2011), pericytes (Katychev et al., 2003), and induced necrosis of
microvessels and osteocytes in the co-femoral articulation and
bruises (Allen et al., 2003; Hu et al., 2006).
The possibility that higher doses of corticosteroids may exert
further direct effects on an established microvasculature has
not been extensively explored.
In ophthalmology clinics, GCs are commonly used to treat
ocular inflammation as well as macular edema of inflammatory
and non-inflammatory origins such as diabetic retinopathy or
retinal vein occlusion. As chronic use is often required, high
doses of the hydrophobic triamcinolone acetonide (TA) or poly-
meric implants releasing Dexa for sustained periods are used to
reduce the frequency of intraocular administrations (Behar-
Cohen, 2011). In addition, ocular tissues are resistant to the use
of GCs due to the high concentration of endogenous steroid
(Knisely et al., 1994), explaining the high concentrations (about
1 mg/ml) used clinically. GCs exert rapid and striking effects on
retinal edema (Miyamoto et al., 2006) but are associated with po-
tential side effects on the posterior segment of the eye including
a reduction of the choroidal vascular network, decreased retinal
vessel diameter in rats, and a decrease in the retinal vascular
density in the developing retinal vasculature (Hartnett et al.,
2006; Valamanesh et al., 2009). Whether GCs directly affect en-
dothelial cell viability has not been fully explored.
On the one hand, when compared with bone, muscle, or skin
where the vasculature undergoes constant remodeling, retinal
endothelial cells proliferate at a very slow rate under normal
conditions (Joussen et al., 2007). On the other hand, GCs have
failed to demonstrate anti-angiogenic effects on retinal or
choroidal neovascularization (Chan et al., 2011; Geltzer et al.,
2013) suggesting that GCs may exert different effects on
endothelial cells derived from different tissue origin. We have
previously shown that clinical doses of intraocular TA induced
a caspases-independent apoptosis associated with the absence
of TUNEL labeling on bovine retinal endothelial cells in culture
and in retinal neovessels (Torriglia et al., 2010; Valamanesh
et al., 2009). This suggested that non-classical mechanisms of
cell death such as autophagy, caspases-independent apoptosis,
or necrosis (Galluzzi et al., 2012) could be involved in GCs
toxicity.
Taken together, these results suggest that the molecular
mechanisms underlying GCs effects on the vasculature are
complex and involve different cellular and molecular pathways
depending on the endothelial cell type, the GC concentration,
and duration of exposure.
The aim of this study was to compare the potential toxicity
of commonly used GCs (Le Jeunne, 2012) on vascular endothelial
cells of different origin and to investigate the underlying mech-
anisms of toxicity of the different GCs. This is particularly im-
portant given that the evaluation of toxicity relies frequently on
caspases-dependent markers and could be underestimated if
other molecular mechanisms are involved. The relevance of our
in vitro findings was assessed by analyzing GCs effects on rat
retinal explants.
MATERIALS ANDMETHODS
Animals. Adult male Lewis rats (6–8 weeks old; Janvier, Le
Genest-Saint-Isle, France) were used for the ex-vivo experi-
ments. Rats were sacrificed using carbon dioxide inhalation. All
experiments were performed in accordance with the European
Communities Council Directive 86/609/EEC and approved by the
local ethical committee of University Paris Descartes.
Human dermal microvascular endothelial cell culture. All culture
media and additives were purchased from Invitrogen (Cergy
Pontoise, France). GCs were purchased from Sigma-Aldrich
(Saint-Quentin Fallavier, France).
Human dermal microvascular endothelial cells (HMECs) are
a transformed cell line transfected with a PBR-322 plasmid con-
taining a region encoding for the SV40 (Simian Virus) gene
(Ades et al., 1992). Cultures were maintained at 37C in a
humidified atmosphere containing 5% CO2. They were cultured
in the endothelial basal medium supplemented with L-
glutamine and HEPES 15mM, 10% complement-free fetal calf
serum (DFCS), and 1% streptomycin (100 mg/ml)—penicillin
(100 units/ml). Confluent HMECs were treated with the LC50 of
GCs: 275 mM Hydro, 255 mM Dexa, 230 mM TA, and 2 mM dexame-
thasone-phosphate (Dexa-Ph) in media supplemented with 2%
of DFCS for 24 h. Although cell survival reaches a plateau with
Dexa-Ph, 2 mM was the concentration giving the most reprodu-
cible results. The hydrophobic GCs (all except for Dexa-Ph) were
previously dissolved in ethanol 100% and then in the medium
(ethanol final concentration 1%). This last step was introduced
in order to have a known concentration of the GCs in the treat-
ment media. Actually, without this step, hydrophobic GCs such
as TA, for instance, precipitate in aqueous medium. This alters
the real concentration of the GC and generates crystals that pre-
cipitate, stick to cells, and cause mechanical damage.
Bovine retinal endothelial cell culture. Bovine retinal endothelial
cells (BRECs) were isolated from the bovine retinal microcircula-
tion as previously reported (Capetandes and Gerritsen, 1990).
BRECs were grown in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with GlutaMAX, 4.5 g/l glucose, 10%
decomplemented fetal calf serum (DFCS), 1% streptomycin
(100 mg/ml)—penicillin (100 units/ml), 0.5% fungizone-ampho-
tericine, and 20 ng/ml basic Fibroblast Growth Factor (FGFb).
Cultures were maintained at 37C in a humidified atmosphere
containing 5% CO2. Confluent BRECs were treated with LC50 GCs
1.37 mM for Hydro, 765 mM Dexa, 460 mM TA, and 2 mM for Dexa-
Ph in media supplemented with 2% DFCS for 24 h. The hydro-
phobic GCs (all except Dexa-Ph) were previously dissolved in
ethanol 100% then in the medium (ethanol final concentration
1%). This cell line was chosen due to the difficulties of obtaining
an equivalent from human origin.
Rat retinal explants. After enucleation, rat retinas were isolated
immediately under aseptic conditions. They were flattened by 4
orthogonal incisions, then transferred onto a Cyclopore 0.2 mm
polycarbonate membrane (Whatman, Maidstone, UK), and
mounted with the vitreal side up. The support membranes were
placed in 6-well tissue culture plates containing 2 ml DMEM
supplemented with 10% steroid-free FCS, 1% penicillin-strepto-
mycin, and 0.1% amphotericin-B. Explants were treated with
LC50 of BRECs as described for cultured BRECs.
MTT Assay. The MTT assay is a colorimetric test that was devel-
oped to determine the survival and growth of eucaryotic cells in
proliferation or to evaluate cytotoxicity (Mosmann, 1983). The
ability to reduce the tetrazolium salts by HMEC and BRECs was
used to evaluate the toxicity and LC50 of GCs. Briefly, cells were
seeded in a 24-multi-well plates at a density of 5 104 cells in
1 ml of complete medium. Confluent cells were treated during
24 h with increasing concentrations of CGs. At the end of the
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treatment, 250 ml of CellTiter 96 Non-Radioactive Cell
Proliferation Assay (MTT; Promega, G4000) (5 mg of MTT per ml
of phosphate-buffered saline) was added to each well, including
6 wells that contained only medium or medium containing 1%
ethanol (controls). Plates were then incubated for 1 h at 37C in
the dark and analyzed with a microplate reader (BioRad
Benchmark, Paris, France) at 570 versus 630 nm. Experiments
were performed in triplicate and repeated 3 times.
Caspases Inhibition
Thirty minutes prior to treatment, HMECs were incubated in
10 mM benzoyloxycarbonyl-val-ala-asp-fluoromethyl ketone
(ZVAD-FMK) (ApexBio A1902). Treatment was initiated by add-
ing GCs at the LC50 concentrations in the same medium.
Controls included 0.2% Dimethyl sulfoxide (DMSO), the vehicle
of ZVAD (not shown). Etoposide treatment, 100 mM for 24 h, was
used as a positive control of caspases activation. Cell survival
was measured by the MMT method.
Internucleosomal DNA Degradation
Internucleosomal DNA degradation assay was performed as
described by Zhua et al. (Ning Zhua 1997). Briefly, cells from
each condition were obtained by scraping in culture medium. A
cell pellet was obtained by centrifugation at 173 g for 10 min,
then the pellet was extracted in 30 ml of sarkozyl (50mM of Tris,
10mM of EDTA, 2% of N-lauryl sarcosine at pH 7.5) and immedi-
ately stored on ice. The cellular lysates were then treated for 2 h
with 1 ml of proteinase K 20 mg/ml at 45C, and 1 ml of RNase-A
10 mg/ml for 1 h at 37C. Finally, the DNA samples were run in a
Tris-acetate-EDTA 2% agarose gel and visualized by staining
with ethidium bromide.
Lactate Dehydrogenase Assay
Lactate dehydrogenase (LDH) is a cytoplasmic enzyme not
released during active cell death like apoptosis, paraptosis, or
autophagy, but released in necrosis due to the early increase of
plasma membrane permeabilization. The LDH assay was per-
formed according to the manufacturer’s instructions of the LDH
Cytotoxicity Detection Kit (Roche Applied Sciences). Following
GCs treatment, an aliquot of culture supernatant was immedi-
ately stored on ice. Cells incubated with 1% Triton-X100 repre-
sented the positive control (100% of LDH release). The
enzymatic reaction was initiated by the addition of 100 ml of
reaction mixture (provided in the kit) with 100ml of supernatant
during 30 min at room temperature. Reaction products were
assessed spectrometrically at an absorbance of 490 versus
630 nm in 96 multi-well plates. The percentage of lysed cells
was calculated using the following formula: 100 [(experimen-
tal LDH release)/(maximum LDH release)]. The maximum of
LDH release corresponding to the amount of LDH released by a
total lysis of the cells with Triton-X100. These experiments
were performed 4 times.
Indirect Immunofluorescence Experiments
Cells were seeded at density of 5 104 cells in 1 ml of complete
medium in Lab-Tek devices (4 wells, Glass slide). Confluent cells
were treated with LC50 of GCs at the indicated concentrations
according to the cellular origin. The following proteins were
tested: Light Chain 3 (LC3), cleaved Caspase-3, apoptosis induc-
ing factor (AIF), and leukocyte elastase inhibitor (LEI)-derived
DNase II (LEI/L-DNase II). At the end of the treatments, cells
were washed 3 times with phosphate buffer saline (PBS), fixed
with 4% paraformaldehyde for 15 min at room temperature,
washed 3 times in PBS, permeabilized with 0.3% de Triton-X100
for 15 min, washed 3 times with PBS for 5 min, and then satu-
rated with 1% bovine serum albumin (BSA) in PBS for 1 h. Slides
were then incubated with the polyclonal antibody against LC3
(Santa Cruz Biotechnology, sc-16756) and monoclonal antibody
against AIF (EPITOMICS, ab32516) diluted 1:100 in PBS-0.1% BSA,
overnight at 4C, washed 5 times with PBS, incubated with the
secondary antibodies: anti-goat (Invitrogen, A11055, Alexa
Fluor) and anti-rabbit (Invitrogen, A10040, Alexa Fluor) diluted
1:200 in PBS and incubated for 1 h at room temperature in a
humidified chamber. Cells were then washed 3 times with PBS
in the dark and finally mounted with Fluoromount (Sigma Life
Sciences). For LEI/L-DNase II, cell labeling was performed as
described before (Altairac et al., 2003). For cleaved Caspase-3
labeling, after fixation and permeabilization performed as
above, cells were washed 3 times with PBS and then saturated
with 1% skim milk in PBS for 1 h. Cells were then incubated
with monoclonal antibody against active Caspase-3 (Cell
Signaling, 9661S) diluted 1:100 in 0.1% skim milk PBS, overnight
at 4C, washed 5 times for 5 min with PBS, incubated with
the secondary antibody (Invitrogen, A10040, Alexa Fluor anti-
rabbit) diluted 1:200 in PBS, for 1 h at room temperature in
a humidified chamber. Cells were then washed 3 times with
PBS in the dark and finally mounted with Fluoromount
(Sigma Life Sciences). Cells were observed using a fluorescence
microscope Olympus BX51, equipped with 40and
60objectives. Confocal analysis was performed using a Zeiss
LMS710 microscope. Adobe Photoshop was used as the elaborat-
ing software.
Cytoplasm and Nucleus Fractions. Cells were collected by trypsini-
zation and rinsed twice in PBS, then, 2 106 cells were resumed
in 500 ml of a hypotonic solution of MgCl2 (1.5mM) during 10 min.
Cells were then crushed with a Dounce potter and centrifuged
for 10 min at 390 g. The cytoplasmic fraction contained in the
supernatant was removed and the nuclear fraction was resus-
pended in 1 ml of MgCl2 (1.5mM) and centrifuged for 10 min at
390 g twice, then resuspended in 200 ml of 10mM Tris, 60mM
NaCl, 200mM sucrose pH 7.4.
To measure the concentration of proteins in both cellular
fractions, 10 ml of the cytoplasmic and nuclear fractions were
mixed to 250 ml of reactive solution (Pierce BCA Protein Assay
Kit, 23225) in a 96-multi-wells plate. The plate was incubated for
30 min at 37C then the optical density was read in a BioRad
Benchmark plate reader at 595 nm. The obtained measures
were correlated to a standard curve of bovine serum albumin
(BSA) made in duplicate (0–1200mg/ml). The sample concentra-
tion was calculated by linear regression.
Western Blot Analysis
Cells were disrupted in RIPA buffer (50mM Tris, 150mM NaCl,
1% Triton-X100, 1% sodium deoxycholate, and 1% sodium
dodecyl sulfate) or M-PER buffer (Thermo Scientific, 78503) in
the presence of protease and phosphatase inhibitors. The pro-
tein concentration was determined by the BCA method (as pre-
viously described). The proteins were distorted in Laemmli
(62mM Tris-HCl 6.8 pH, 2% SDS, 10% glycerol, 5% b-mercaptome-
thanol, and 0.01% bromophenol blue). Equal amounts of protein
(20 mg) were separated on a 12% Tris-glycine gel. Nitrocellulose
membrane transfer was performed at 100 V for 1:30 h at 4C and
monitored by the membrane staining with Ponceau Red (Sigma-
Aldrich). The membrane was saturated with 5% skim milk in
PBS for 1 h at room temperature then incubated overnight at 4C
with the primary antibodies against Caspase-3 (1:1000) (Santa
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Cruz, 1224), cleaved Caspase-3 (1:1000) (Cell Signaling, 9661), AIF
(1:1000) (Santa Cruz, 9416), LEI/L-DNase II (1:1000) (Torriglia et al.,
1995), b-actin (1:1000) (Santa Cruz, 1616), Lamin B (1:1000) (Santa
Cruz, 6216), and LC3-II (1:1000) (Santa Cruz sc-16756). After 5
washes in PBS containing 0.1% Tween-20, the membrane was
incubated for 1 h with the anti-rabbit (Victor Laboratories,
PI-1000) or anti-goat (Victor Laboratories, PI-9500) secondary
antibodies conjugated to peroxidase, diluted 1:5000, in PBS con-
taining 0.5% skim milk and then washed 5 times in PBS. Poly
ADP-ribose polymerase (PARP) Western blot was performed as
already described by Blenn et al. (2006). Visualization of the
immunoreactive bands was obtained by a chemoluminescent
substrate, SuperSignal West Pico Chemiluminescent Substrate
(Thermo scientific, 34087) using a MicroChemi 4.2 DNR
BioImaging System.
Retinal Flat Mounting
After GCs treatment, retinas were immediately washed and
fixed with 4% paraformaldehyde for 15 min. They were then
permeabilized with PBS containing 0.1% Triton X-100, and incu-
bated with the rabbit anti-Caspase-3 and mouse anti-von
Willebrand antibody or the chicken anti-LEI, and rabbit anti-von
FIG. 1. Evaluation of the toxicity and lethal dose (LC50) of different glucocorticoids (GCs) on human endothelial cells (HMECs) or bovine retinal endothelial cells (BRECs).
Cells were treated with hydrocortisone (Hydro), triamcinolone acetonide (TA), dexamethasone (Dexa), dexamethasone-phosphate (Dexa-Ph) for 24 h at the indicated
concentrations. The lipophilic GCs (Hydro, TA, and Dexa) were dissolved in ethanol 100% then in cell culture medium. Control cells were either exposed to 1% ethanol
or were left untreated. Cell viability was evaluated using the MTT assay. A, HMEC; B, BREC. The lipophilic GCs show a concentration-response relationship between the
decline of viability and the increase of the dose while Dexa-Ph is less toxic. These are representative results of 3 different experiments.
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Willebrand (1:100) overnight at 4C. After washing 5 times with
PBS, retinas were incubated with the secondary antibody (Alexa
Fluor 405-conjugated goat anti-rabbit IgG and Alexa Fluor 594-
conjugated Donkey anti-mouse IgG or Alexa Fluor 568-conju-
gated goat anti-chicken IgG, and Alexa Fluor 405-conjugated
goat anti-rabbit IgG (1:200)) for 1 h. For phosphatase treatment,
retinas were incubated for 30 min at 37C with calf intestinal
alkaline phosphatase (Invitrogen, 8009-019) in dephosphoryla-
tion buffer (Invitrogen, P/N 01371) then washed 3 times.
Dephosphorylation was performed to unmask 30-OH DNA
extremity stemming from activation of L-DNase II. Finally,
Retinas were fixed with 4% paraformaldehyde then incubated
for 1 h with 80 ll of terminal deoxynucleotidyl transferase dUTP
nick end labeling assay (TUNEL, Roche Diagnostics, Mannheim,
Germany) reaction mixture at 37C. The retinas were flat
mounted using Fluoromount. Images were taken using a
confocal laser scanning microscope Zeiss LSM 710 (Oberkochen,
Germany).
FIG. 2. Cell death in GCs treated HMEC cells. A, The activation of autophagy process was evaluated by anti-LC3 immunocytochemistry. HMECs were treated for 24 h
with the LC50 of GCs. They were then fixed, permeabilized, and immunostained with anti-LC3 (green). For the positive control, cells were incubated with medium lack-
ing amino acids (arrow heads). All treatments revealed diffuse cellular labeling of LC3 confirming the absence of autophagic vesicles. Scale bars represent 5 mm. B, Cells
treated as above were analyzed by Western blot. The activation of autophagy in AA deprived cells triggers the appearance of a 14 kDa band, LC3II, the lipidated form of
LC3. C, DNA extracted from HMEC treated with LC50 of GCs was analyzed by electrophoresis on a 2% agarose gel. Oligonucleosomal fragments of DNA are seen with
Dexa, Dexa-Ph, and slightly with TA. Control: untreated cells, ethanol 1%: medium containing 1% of ethanol, treatment with 40 mm 5 -N, N-hexamethylene-amiloride
(HMA) was used as a positive control for apoptosis. D, The release of lactate dehydrogenase (LDH) from HMECs treated 24 h with LC50 of GCs was measured in the cul-
ture medium and compared with the maximal LDH release, determined by exposing the cells to 1% of Triton X-100. Each experiment was performed in triplicate. Data
are expressed as medium percentage of LDH released into the media. Dexa induced an increased release of LDH when compared with control and to the other treat-
ments (**P0.01). This is a representative experiments out of 4.
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Statistics
Data were expressed as means6SE. Statistical analysis was per-
formed using the Graphpad Prism5 program (Graphpad Software,
San Diego, California). Mann-Whitney test comparison was used.
P< 0.05 deemed significant, unless otherwise stated.
RESULTS
Dose-Dependent Effect of GCs on Microvascular Endothelial Cells
Viability (HMEC, BREC) and Lethal Concentrations (LC50)
determination
In order to evaluate the sensitivity of HMEC and BREC to
corticosteroids, cells were treated with different concentrations
of Hydro, TA, Dexa, and Dexa-Ph for 24 h. Because
hydrophobic GCs (Hydro, TA, and Dexa) form dense and adher-
ent toxic aggregates when directly added to culture medium
(Szurman et al., 2007), they were first dissolved in ethanol 100%,
then in the culture medium. This gave a final concentration of
1% ethanol in the medium. The reduced viability measured by
the MTT assay was correlated to a reduced number of living
cells, as verified by the trypan blue assay (not shown). Figure 1
shows that GCs had different concentrations-dependent reduc-
tion of cell viability, depending on the GC and the cell type.
Dexa-Ph was the least toxic and HMECs were more sensitive
than BRECs.
The Mechanisms of Cell Death Induced by GCs
In order to analyze the mechanisms underlying GC toxicity on
endothelial cells, we successively evaluated markers for
autophagy, necrosis, caspases-dependent and caspases-inde-
pendent apoptosis. These analyses were performed on HMEC
FIG. 3. The activation of caspases in GCs treated HMECs. A, The activation of Caspase-3 by immunolabeling of HMECs using an anti-active Caspase-3 antibody (red).
Cells were exposed for 24 h with the LC50 of GCs. Cells incubated with etoposide were used as positive control. Only Dexa and Dexa-Ph induced an activation of
Caspase-3 (higher magnifications below). These are representative results out of 3 independent experiments. Scale bars represent 7 mm. B, Caspase-3 and PARP
Western blot analysis. Protein extracts from GCs-treated HMECs were analyzed in a 12% acrylamide gel, transferred to nitrocellulose and revealed with anti-Caspase-3.
Apoptosis induced in HMECs with etoposide (100mM for 24 h) was used as positive control. Activated Caspase-3 and cleaved PARP were detected in HMECs treated with
Dexa and Dexa-Ph, showing that both GCs induce Caspase-3 activation. Representative results of 3 experiments. C, Effect of ZVAD on HMEC survival. Cells were
exposed for 24 h with the LC50 of GCs in the presence (gray bars) or in the absence (white bars) of ZVAD-FMK. Cells incubated with Etoposide were used as positive con-
trol. MTT was used to evaluate cell viability. No protective effect is seen in GCs-treated cells. Results were analyzed by the ANOVA test using the Newman-Keuls post
test. Asterisks (***) indicate significant differences P<0.001.
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using for each steroid the LC50 as determined above in order to
have the same degree of toxicity.
Autophagy
The presence of autophagy was analyzed using an antibody
against MAP-LC3 (microtubule-associated protein 1 light chain 3).
This protein is integrated into the autophagosomes membranes
(Tanida et al., 2004). Under physiological conditions, the quies-
cent LC3 has a diffuse distribution in the cytoplasm. Once the
autophagy is activated, LC3 concentrates in the autophagosome
membrane and gives a punctuate labeling as observed in cells
cultured in a depleted amino-acid (AA) medium, used as a posi-
tive control (Fig. 2A). No such labeling was observed with GCs
treatment eliminating autophagy as a potential mechanism of
cell death (Fig. 2A). This result was confirmed by Western blot.
As seen in Fig. 2B, lipidated form of LC3 (LC3 II) only appeared in
the AA depleted medium.
DNA Damage and Necrosis
DNA fragmentation into oligonucleosomal fragments is a well-
recognized hallmark of apoptotic cell death, as induced by 5 -N,
N-hexamethylene-amiloride (HMA) (used as a positive control).
The “DNA ladder” pattern was clearly seen in samples
treated with Dexa and Dexa-Ph, faintly with TA treatment and
not at all in Hydro-treated cells (Fig. 2C). Moreover, since a
degree of smear degradation was observed, we investigated
whether necrosis was involved by measuring the release of LDH
in the culture medium. A total lysis of the cells induced by 1%
Triton-X100 was used as a positive control. Among the
GCs tested at their respective LC50 concentrations, only
Dexa (255mM) induced a significant increase of LDH release
(31.17%; **P 0.01) when compared with the positive control
(Fig. 2D).
Caspases-Dependent Apoptosis in GCs Toxicity
Caspase-3 activation was analyzed by immunocytochemistry
(Fig. 3A) and Western blot (Fig. 3B). Among the GCs tested at
their respective LC50 concentrations, only Dexa and Dexa-Ph
induced activation of Caspase-3 as observed on immunocyto-
chemistry (Fig. 3A). This was confirmed by Western blot
(Fig. 3B). Only Dexa and Dexa-Ph induced the cleavage of
pro-Caspase-3. Moreover, PARP-1, one of the main targets of
FIG. 4. Activation of the L-DNase II pathway in GCs-treated HMECs. A, HMEC cells were treated with the LC50 of GCs for 24 h and immunostained with an anti-LEI/L-
DNase II (red). HMECs exposed to HMA represent the positive control. All the GCs led to LEI/L-DNase II activation with an intense nuclear staining (arrow heads). Scale
bar represents 10 mm. These are representative results out of 4 experiments. B, GCs-treated HMECs were fractionated into cytoplasmic and nuclear fractions. Western
blot analysis using an anti-LEI/L-DNase II revealed an accumulation of L-DNase II in the nucleus of treated cells, phenomena also seen in HMA-treated cells used as pos-
itive control.
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activated Caspase-3 was cleaved in cells treated with Dexa and
Dexa-Ph but not in cells treated with other GCs (Fig. 3B). In all
these experiments, the treatment of cells with etoposide, an
inhibitor of topoisomerase II, known to induce caspases-
dependent cell death was used as a positive control. The
involvement of caspases in cell death was evaluated using the
pancaspase inhibitor ZVAD-FMK. Results are seen in Figure 3C.
The inhibitor successfully inhibits cell death in etoposide but
not in GCs-treated cells, suggesting that this pathway is not the
main effector in GCs cell demise.
Caspases-Independent Apoptosis in GCs Toxicity
Due to the lack of caspases activation in TA and Hydro, as well
as the lack of protection with pancaspase inhibitor, we analyzed
caspases-independent pathways, namely LEI (LEI/L-DNase II)
and AIF.
LEI is a cytoplasmic molecule owning an anti-protease activ-
ity. After induction of apoptosis it is cleaved and transformed
into L-DNase II, a molecule that has an endonuclease activity
and that is translocated to the nucleus (Padron-Barthe et al.,
2007).
The activation of L-DNase II was estimated by immunostain-
ing and Western blot. L-DNase II activation and nuclear translo-
cation were observed with all GCs (Fig. 4A). In order to verify the
nuclear translocation of this protein, we fractionated the cyto-
plasm from nucleus, and performed a Western blot on both
fractions (Fig. 4B). We observed the presence of native LEI
(42 kDa) in the cytoplasmic fractions while the nuclear fractions
contained, in addition, one band of 35 kDa corresponding to the
active L-DNase II (Belmokhtar et al., 2000). Taken together these
results indicate that GCs activate the LEI/L-DNase II pathway.
HMA-treated cells were used as positive control of L-DNase II
activation.
Concerning AIF (Fig. 5), HMECs treated with the GCs pre-
sented a cytoplasmic dotted labeling that was compatible with
its classical mitochondrial localization. This localization was
not seen to be modified by the GCs (Fig. 5A). Observe that
staurosporine-treated cells used as positive control of AIF acti-
vation showed a diffuse cytoplasmic labeling and a nuclear
peripheral labeling. As previously done, we verified this result
by Western blot (Fig. 5B) after nuclear-cytoplasmic fractiona-
tion. The activated, cleaved form of AIF is only seen in stauro-
sporine-treated cells. These results indicate that the AIF is not
activated by GCs in HMECs.
Effect of GCs on BREC
To verify whether the cellular phenomena induced by the GCs
on the HMEC were reproducible on retinal endothelial cells, we
analyzed the activation of the cell death pathways previously
studied.
For this purpose, BRECs were treated for 24 h with LC50 then
the activation of Caspase-3, LEI/L-DNase II, and AIF were esti-
mated by immunostaining with the corresponding antibody.
The activation of Caspase-3 was observed on BREC treated with
Dexa and Dexa-Ph, as already indicated for HMEC. Hydro and
TA did not induce the Caspase-dependent cell death (Fig. 6C).
Similarly, the activation of the LEI and nuclear translocation of
L-DNase II were observed with all GCs on BREC (shown in higher
magnifications) (Fig. 6A). The analysis of the immunocytochem-
istry of AIF on BREC showed a cytoplasmic dotted labeling
FIG. 5. AIF activation in GCs-treated HMECs. A, Nuclear translocation of AIF was evaluated by anti-AIF immunocytochemistry (green). HMECs were treated for 24 h with
the LC50 of GCs, for the positive control cells were treated with Staurosporine (Stauro). Control cells and GCs-treated cells revealed a dotted labeling of AIF. Scale bars
represent 10 mm. These are representative images of 2 independent experiments performed in quadruplicate. B, AIF Western blot was performed on nuclear and cyto-
plasmic fractions. AIF was present in all cytoplasmic fractions, only the Staurosporine-treated cells, used as a positive control, show a nuclear translocation of the
truncated (active) form of AIF. Representative experiments out of 2.
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indicating the mitochondrial localization of AIF with all GCs
treatments, while cells treated with the staurosporine (positive
control) revealed a diffuse labeling in the cytoplasm and a
nuclear translocation (Fig. 6B).
Impact of GCs on the Retinal Microvasculature
The in vitro experiments described above demonstrated the
toxic effects of GCs on HMEC and BREC. In order to mimic phys-
iological conditions more closely, where the endothelial cells
are organized as microvascular networks, rat retina explants
were treated with GCs for 24 h at the LC50 determined for BREC
cells. An “ex vivo” model was preferred to an “in vivo” approach
in order to better control the concentration of GCs reaching the
retinal vascular bed. During intravitreal administration of drugs
in rodents, due to the relatively large lens, there is a non-
homogeneous distribution of the injected substance and an
uneven concentration reaching different parts of the retina. The
retinal microvasculature was immunostained with anti-Von
FIG. 6. The activation of caspases-dependent and independent cell death in GCs-treated BRECs. For all experiments, BREC were treated during 24 h with LC50 of GCs. A,
BRECs were immunostained with an anti-LEI/L-DNase II. Cells exposed to HMA represent the positive control. All the GCs led to LEI/L-DNase II activation with an
intense nuclear staining (white arrow heads) the same outcomes was observed previously with HMEC. LEI/L-DNase II was stained in red, nuclei in blue. The right col-
umn represents confocal images of cells showing a nuclear translocation of L-DNase II. Scale bars represent 20 mm for fluorescence images and 10 mm for confocal
images. B, Nuclear translocation of AIF in BREC was evaluated by anti-AIF immunocytochemistry. Cells treated with Staurosporine represent a positive control. GCs-
treated cells revealed a dotted labeling of AIF, which suggests a mitochondrial localization. White arrow head shows a nuclear translocation of AIF. AIF is seen in green,
nuclei in blue. Scale bars represent 20 mm for fluorescence images and 10 mm for confocal images. C, Activated Caspase-3 immunocytochemistry of BRECs. BRECs were
immunostained with an antibody that specifically recognizes the cleaved Caspase-3. Etoposide was used as a positive control. Like previously observed with HMECs
only Dexa and Dexa-Ph induced an activation of Caspase-3 (arrow heads and magnifications). Activated Caspase-3 is seen in red, nuclei in blue. Scale bars represent
20mm. All experiments were performed at least 4 times.
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Willebrand antibody. The double immunolabeling anti-caspase
with TUNEL assay or anti-LEI/L-DNase II with TUNELþ
phosphatase assay allowed us to analyze the activation of these
cell death pathways. As for HMEC and BREC, LEI/L-DNase II was
activated on retina microvascular cells with all tested GCs as
observed in our in vitro experiments (Fig. 7A). The activation of
Caspase-3 was observed in Dexa and Dexa-Ph treatments,
whereas Hydro and TA did not induce a caspases-dependent
cell death (Fig. 7B).
DISCUSSION
Intraocular GCs are widely used to treat retinal diseases, directly
injected into the vitreous as a non-soluble crystal suspension
FIG. 7. Cell death pathway induced by GCs on retinal microvasculature. Retinas from Lewis rats were flat mounted, treated with GCs, and analyzed. The retinas treated
with steroids-free medium were used as control. A, Retinal explants were treated with GCs, and immunostained for LEI/L-DNase II (red), TUNEL-phosphatase (green),
and won Willebrand factor (blue). L-DNase II was activated with all treatments. Magnifications of cells displaying L-DNase II activation are seen on the right. B, Retinal
explants were treated with GCs, and immunostained for Caspase-3 (blue), TUNEL (green), and won Willebrand factor (red). The activation of Caspase-3 on retina ves-
sels was induced with Dexa. Scale bar represents 30 mm. Each experiment was performed at least 4 times.
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(such as TA) or more recently as polymeric poly-lactic-co-
glycolic acid implants releasing Dexa. The choice of the GC is
empirical since very few studies have compared their potential
toxic and beneficial effects. In this study, we investigate the
potential toxicity of GCs on the microvasculature. We have
focused on the established microvasculature rather than neo-
vascularization which has already been featured in previous
studies. Cellular models have limitations and extrapolation to
clinical conditions or to established tissues should be performed
with caution. In our experiments, we use confluent cells, so that
our experimental conditions are closer to established vessels
than to proliferating vessels. In our retinal explants, we evalu-
ate resting vessels rather than proliferating vessels. We compare
two cell lines of dermal and retinal origin in order to investigate
the differences in toxicity and we further evaluated the underly-
ing mechanisms of different GCs toxicity. Our results show that
endothelial cells originating from the retina (BREC) are less sen-
sitive to all the GCs tested when compared with endothelial cells
from dermal origin (HMEC). Although the cells are from different
origins in terms of species and the cells have different culture
conditions, various factors concerning the tissue origin of the
cells could explain the difference in GCs sensitivity. The first fac-
tor could be the natural microenvironment of these cells. In the
eye, cortisol levels are higher than in the circulation and the cor-
ticoid-binding globulin is absent, explaining in part the immuno-
logic privilege of the intraocular media (Denniston et al., 2011).
Moreover, in inflammatory conditions, as shown in experimen-
tal models of uveitis, cortisol levels increase in the ocular media
(Bousquet et al., 2012). This permanent exposure to high cortisol
levels associated with the low proliferating capacity of retinal
endothelial cells may explain their higher resistance to GCs-
induced cell death (Joussen et al. 2007).
Although the tested drugs belong to the same pharmacologi-
cal family, they show different cellular toxicity. One might
think that these different effects could be related to their relative
affinity for glucocorticoid or mineralocorticoid receptors (Chen
et al., 2002). However, the concentrations of GCs used here are
greater than the binding constant of these receptors (in the
micromolar range), the receptors are completely saturated, sug-
gesting that the toxic effects are receptor independent.
Concerning endothelial cell toxicity, our results show that
hydrophilic GC, Dexa-Ph is less toxic than the lipophilic, Hydro,
Dexa, and TA. This difference may be explained, by hydrophilic
GCs transferring less easily through the intact membranes,
resulting in lower bioavailability in cells and less toxicity. It is
worth noting that the toxicity measured here is not related to
the anti-inflammatory activity of these compounds. Compared
with Hydro, TA has 5 - to10-fold greater anti-inflammatory
activity, whereas Dexa has 20 - to 40-fold greater activity.
However, their LC50 values are quite similar (255mM for Dexa
and 230mM for TA) (Cohen and Jacquot, 1981; Le Jeunne, 2012).
TA is the most widely administered intraocular GC and is usu-
ally given in a formulation not specifically adapted to ophthalmo-
logical use, as it was originally designed for intramuscular and
intra-articular administration. Studies on the toxicity of TA and/or
its excipient (benzylic alcohol), the crystalline or soluble formula-
tions, have led to conflicting rather than concluding results
(Torriglia et al., 2010, Valamanesh et al., 2007). Indeed, toxicity of
TA and its excipient was not found in certain studies (McCuen,
1981; Narayanan et al., 2006) while other works clearly established
the toxicity of TA and/or the excipient in the eye, resulting in a
disorganization of the retina layers, a loss of the choroid network
density and a vasoconstriction of the retina blood vessels
(Morrison et al., 2006; Torriglia et al., 2010; Valamanesh et al., 2009).
TA showed concentration and time-dependent cytotoxicity
on retinal pigment epithelium cells, glial cells, and endothelial
cells of the retina. This toxicity triggered a reduction in mito-
chondrial activity, and an activation of caspases-independent
cell death mechanism (paraptosis in EPR cells, LEI-L-DNase II,
and AIF in retinal endothelial cells [Narayanan et al., 2006;
Valamaneshet al., 2007; Yeung et al., 2003]). This may explain the
results obtained by some authors that showed no caspase acti-
vation after 24 h of treatment with TA on primary human retinal
microvascular and flat mounted rat retinas (Hartnett et al., 2006).
Hence, the assessment of cell death pathways is an essential
step in estimating the safety or the toxicity of health products.
We show that different cell death mechanisms other than classi-
cal caspases-dependent apoptosis may be responsible for cell
death induced by GCs and that the same mechanisms seen in
cell culture were also seen ex-vivo (retinal microvessels).
Moreover, the use of the pancaspase inhibitor, ZVAD on HMEC
does not reveal a protective activity with any of the GCs suggest-
ing that caspases are not the main effectors in this cell death.
In this study, the toxicity of several GCs is estimated and
compared for the first time, on microvascular endothelial cells
of different tissue origins. GCs toxicity was previously disre-
garded because the tests used were unsuitable for evaluating
caspases-independent cell death. Strikingly, the concentrations
used in our experiments, which proved to be cytotoxic, were
lower than those used clinically. For instance, 4 mg of TA is usu-
ally injected into the human vitreous to treat macular edema.
This produces a concentration of 1 mg/ml (approximately
2.3mM) of TA in the vitreous (lasting up to 1 month) due to the
slow clearance of drugs in this compartment. The vitreous
humor levels measured by several authors after TA intravitre-
ous injection, are higher than the LC50 found in both HMEC and
BREC (around 4mM when compared with 230 mM and 460mM for
HMEC and BREC, respectively) (Oliveira et al., 2012).
GCs have widespread clinical applications in the eye and in
other organs and their use is often the only available therapeutic
option. In this work, we demonstrate that at high concentrations
these compounds may be toxic to endothelial cells of the micro-
vasculature and other target tissues. It is essential to ensure that
these concentrations remain under the toxic threshold for endo-
thelial cells when developing novel therapeutic protocols.
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